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Efficient iron acquisition is crucial for the pathogenesis ofMycobacterium tuberculosis. Mycobacterial iron uptake and metabo-
lism are therefore attractive targets for antitubercular drug development. Resistance mutations against a novel pyrazolopyrim-
idinone compound (PZP) that is active againstM. tuberculosis have been identified within the gene cluster encoding the ESX-3
type VII secretion system. ESX-3 is required for mycobacterial iron acquisition through the mycobactin siderophore pathway,
which could indicate that PZP restricts mycobacterial growth by targeting ESX-3 and thus iron uptake. Surprisingly, we show
that ESX-3 is not the cellular target of the compound.We demonstrate that PZP indeed targets ironmetabolism; however, we
found that instead of inhibiting uptake of iron, PZP acts as an iron chelator, and we present evidence that the compound re-
stricts mycobacterial growth by chelating intrabacterial iron. Thus, we have unraveled the unexpected mechanism of a novel
antimycobacterial compound.
Iron is an essential nutrient for almost all living organisms.Whileferric iron (Fe3) is nearly insoluble in aqueous solutions under
aerobic conditions and neutral pH, the soluble ferrous iron (Fe2)
is potentially toxic to the cell due to generation of deleterious
oxygen radicals through participation in Fenton chemistry (1).
Thus, the amount of soluble iron is tightly regulatedwithin organ-
isms (1).Mycobacterium tuberculosis, the causative agent of tuber-
culosis (TB), infects macrophages and resides within the low-iron
environment of the phagosome (2, 3). To overcome iron starva-
tion,M. tuberculosis produce high-affinity Fe3-chelating sidero-
phores calledmycobactin/carboxymycobactin (the latter a soluble
variant of mycobactin; here we refer to both as mycobactins) to
enhance iron uptake from the surroundings (4, 5). Nonpatho-
genicmycobacteria, likeMycobacterium smegmatis, produce a sec-
ond structurally different siderophore, exochelin, in addition to
the mycobactins (6, 7). When entering bacterial cells by means of
siderophores, Fe3 is reduced to Fe2 for incorporation into my-
cobacterial iron-containing proteins, including iron storage pro-
teins like bacterioferritin (1). Other known mycobacterial iron
uptakemechanisms include heme uptake (8, 9), internalization of
holo-transferrin (10), and low-affinity iron uptake through outer
membrane porins (11). Guinea pigs and mice infected by M. tu-
berculosis strains deficient in siderophore synthesis or transport
across the cell membrane show a significant reduction in bacterial
burden compared to animals infected by wild-type (WT) M. tu-
berculosis (12, 13), demonstrating the need for iron in mycobac-
terial virulence.
TB is responsible for 1.5million deaths per year, and the grow-
ing resistance toward current TB drugs calls for urgent identifica-
tion of new mycobacterial drug targets (14–16). As part of a
high-throughput drug target identification screen, we previously
identified mutations within the eccB3 gene of the mycobacterial
esx-3 gene cluster which conferred resistance to the novel antitu-
bercular pyrazolopyrimidinone compound PZP {3-(4-chloro-
phenyl)-5-(cyclohexylmethyl)pyrazolo[1,5-]pyrimidin-7(4H)-
one}(15) (Fig. 1A). For potential lead optimization, it is beneficial to
unravel both the target andmechanismof actionof anewcompound
at an early stage of development. In this study, we sought to identify
the target andmechanism of PZP.
The esx-3 gene cluster comprises a set of 11 genes, as indicated
in Fig. 1B, that encode the ESX-3 type VII secretion system (17).
The specific role of eccB3 in ESX-3 function is currently unknown.
Interestingly, ESX-3 is known to be required for the mycobactin-
mediated siderophore iron uptake pathway (18–21). ESX-3 is
essential in M. tuberculosis but not in M. smegmatis, which, in
addition to mycobactins, produces exochelin that functions inde-
pendently of ESX-3. However, ESX-3 is still absolutely required
formycobactin-mediated iron uptake in the latter species (18, 20).
This nonessential nature of ESX-3 inM. smegmatis has previously
proven to be of great advantage when resolving mechanisms re-
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lated to ESX-3 and mycobactin iron metabolism (18). Therefore,
we aimed to unravel the target andmechanism of PZP inM. smeg-
matis. We initially hypothesized that treatment with PZP would
block ESX-3 function and decrease mycobacterial iron uptake.
Paradoxically, treatment with the compound increased bacterial
iron levels, but treated cells behaved as if they were starved for
iron. We found that, instead of acting directly on ESX-3, PZP is a
chelator of Fe2 that apparently deprives the microbe of access to
its own intracellular pools of iron.
MATERIALS AND METHODS
Strains and culture conditions. The parental bacterial strain used in this
study was Mycobacterium smegmatis mc2155 (22), and mutant strains
used in this study are listed in Table 1. Tomonitor growth ofM. smegmatis
strains in iron-deplete or -repletemedium, the bacteriawere first grown to
stationary phase in Middlebrook 7H9 (BD Difco) supplemented with
0.2% glycerol, 0.05% Tween 80, and 10% albumin-dextrose-catalase
(ADC) medium (5% [wt/vol] bovine serum albumin fraction V, 2% [wt/
vol] dextrose, 145.5 mM NaCl, 0.003% [wt/vol] catalase). The cells were
then centrifuged at 3,000  g for 10 min and washed once in chelated
Sauton’s medium prepared as previously described, using Chelex100
(Bio-Rad) (18).When growth of theWT and eccB3(N26)mutant strains
was compared (see Fig. 3C and D, below), cultures were not washed, in
order to slightly relax the low-iron growth conditions. The cultures were
diluted to an optical density at 600 nm (OD600) of 0.01 in chelated Sau-
ton’s medium with 100 M 2,2=-bipyridine (Alfa Aesar) for iron-deplete
(low-iron) conditions or with 150 M FeCl3 for iron-replete (high-iron)
conditions. Growth was monitored in microplate honeycomb wells (Oy
Growth Curves Ab Ltd.), with 200 l in each well, using a Bioscreen
growth curve reader (Oy Growth Curves Ab Ltd.). The growth was also
assessed by growing 10ml of culture in 50-ml plastic tubes andmeasuring
the OD600, using a standard spectrophotometer.
Construction of M. smegmatis mutant strains. An M. smegmatis
mutant unable to synthesize exochelin (fxbA) was created by replacing
the formyl transferase fxbA (MSMEG_0014 [SmegmaList, http:
//mycobrowser.epfl.ch/smegmalist.html]), with the hygromycin resis-
tance (HygR) gene by recombineering (23). A fragment containing the
200 bp flanking fxbA separated by the linker AGATCTGTCCTACTC
GAG, where the underlined sequences are the restriction sites for BglII
and XhoI, was synthesized and cloned into pUC57-simple (Genscript,
USA) (see Fig. S1 in the supplemental material). The HygR cassette was
amplified from pUV15TetORm (24) by using primers BamHIHygF (AG
ATGGATCCTGACGTTCATCCATAGTTGCCTG) and XhoIHygR (AG
ATCTCGAGGCGGCTTTAGCTAATTAATTGG) and cloned into the
BglII and XhoI sites of the flanking sequences. The flanked HygR cassette
was amplified using primers KO_FxbA_F (TTCGCGATGCTCAACCG
CGA) and KO_FxbA_R (CGTCGTTGACCAGGACCACG). Allelic ex-
change with fxbA and the HygR cassette was carried out by transforming
the amplified product into an M. smegmatis strain expressing the myco-
bacteriophage recombinases gp60 and gp61 on a nitrile-inducible, coun-
terselectable episomal plasmid. The recombineering plasmid was re-
moved by counterselecting on 10% sucrose. Successful replacement of
fxbAwith theHygR cassettewas confirmedby Southern blot analysis (data
not shown).
The M. smegmatis point mutants eccB3(R14L), eccB3(N24H), and
eccB3(N26) were constructed by single-stranded DNA recombineering
(25) using the tetracycline-inducible, gp61-expressing vector pKM402 (kind
gift from Kenan Murphy, University of Massachusetts Medical School,
MA, USA). Tetracycline-induced M. smegmatis containing pKM402 was
cotransformed with 1 g of the oligonucleotide RpsL (CGCGCGCGAC
CTTCCGGAGGGCCGAGTTCGGCTTCCTCGGAGTGGTGGTG
TAAACGCGCGTGCACACGCC), which introduced a point mutation in
the M. smegmatis rpsL locus, which confers resistance to streptomycin,
and the oligonucleotide R14L (CTCGTTGACCGGGGTGCGCGAGC
TGAACGAGCGCAGGTCGTCGGGGTTGACGGGGCCGGTATGCCG
GCA), N24H (CCGCGGCGGTACTGCACGCCGTCGGGGTTCTCGT
GGACCGGGGTGCGCGAGCTGAACGAGCGCCGGTCGT), or N26
(GTGACGAAACCGCGGCGGTACTGCACGCCGTCGGGCTCGTTGA
CCGGGGTGCGCGAGCTGAACGAGCGC), which introduced the spe-
cific point mutations in eccB3. RpsL mutants were selected on LB plates
containing 20 g/ml streptomycin, and a mismatch amplification mu-
tation assay (MAMA)-PCR was used to identify the second desired
mutation in the eccB3 gene (26). Positive mutants were confirmed by
sequencing.
Chemicalmaterials.PZPwas synthesized at BioDuroBeijingCo., Ltd.
Ferrozine {3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p=-disulfonic acid
monosodium salt hydrate}, ferrous sulfate heptahydrate, and hydroxyl-
amine hydrochloride were purchased from Sigma-Aldrich. PZP was dis-
solved in dimethyl sulfoxide (DMSO), ferrozine was dissolved in deion-
ized water, and ferrous sulfate heptahydrate was freshly prepared in 0.1M
HCl. Hydroxylamine hydrochloride was dissolved in 2 N HCl (final con-
centration, 1.4 M). The solutions were kept at 4°C until use.
TABLE 1 Strains used in this study
M. smegmatis
strain Reference
Siderophore(s)
produceda
Functional siderophorea
iron uptake pathway(s)
mc2155 22 M, E M, E
esx-3 18 M, E E
esx-3 fxbA::pSES 18 M None
fxbA This study M M
eccB3(R14L) This study M, E M*, E
eccB3(N24H) This study M, E M*, E
eccB3(N26) This study M, E M*, E
a M, mycobactin/carboxymycobactin; E, exochelin; *, unverified.
FIG 1 Clones of M. tuberculosis resistant to PZP have mutations in the eccB3
gene of ESX-3. (A) Chemical structure of PZP. (B) The esx-3 gene cluster is
composed of 11 genes stretching fromMSMEG_0615 to MSMEG_0626 inM.
smegmatis (SmegmaList, http://mycobrowser.epfl.ch/smegmalist.html) and
rv0282 to rv0292 in M. tuberculosis (TubercuList, http://tuberculist.epfl.ch
/index.html). (C) Amino acid sequence of the N-terminal end of EccB3. Black
highlighting indicates conserved residues inmycobacteria. Orange, green, and
red circles indicate the locations of mutated residues in PZP-resistant M. tu-
berculosis (R14L, N24H, andN26mutations). (D) EccB3 is a transmembrane
protein with a predicted small (the first 71 amino acids) cytosolic tail on the N
terminus and a large (amino acid 95 to 538) extracellular C-terminal domain.
The mutations R14L, N24H, and N26 are localized to the cytosolic tail, as
indicated.
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M. smegmatis sensitivity assay. Determination of the M. smegmatis
PZP MIC under iron-replete conditions was based on a resazurin micro-
titer assay (27). Briefly, M. smegmatis was grown to stationary phase be-
fore dilution to an OD600 of 0.001, added in triplicate to 96-well plates,
and grown with shaking at 37°C in the presence of increasing concentra-
tions of PZP for 24 h before addition of 0.02% of resazurin (Sigma). The
cultures were incubated for another 16 h before the color of the cultures
was analyzed. Pink and blue distinguishes metabolically active and inac-
tiveM. smegmatis cultures, respectively. The PZPMICunder iron-deplete
conditions was determined by monitoring growth in increasing concen-
trations of compound in a Bioscreen growth curve reader; the MIC was
defined as the lowest concentration of PZP that prevented growth after 60
h growth with shaking at 37°C.
Iron content analysis.Whole-cell metal content was measured inM.
smegmatis WT and eccB3(N26) mutant strains grown to the late expo-
nential phase in low- or high-iron Sauton’s medium and in the presence
or absence of 25 M PZP for 24 h. Cells were washed three times in 5 ml
of buffer containing 50 mM HEPES (pH 7.5) and 500 mM NaCl (all
glassware was previously rinsedwith deionizedH2Oplus 5%HNO3, trace
metal grade). The samples were resuspended in 100 l deionized H2O,
and a 10-l aliquot was used for protein content determination (28). The
remaining 90l of each samplewas acid digestedwith 200l HNO3 (trace
metal grade) for 1 h at 80°C and overnight at 20°C. Digestions were con-
cluded after addition of 60 l of 30% H2O2 and dilution to 2 ml with
water.Metal content in digested samples wasmeasured by atomic absorp-
tion spectroscopy (Analyst 300; PerkinElmer, Foster City, CA, USA).
RNA extraction and quantitative RT-PCR. Total RNA extraction,
cDNA synthesis, quantitative reverse transcription-PCR (RT-PCR), and
analysis were performed as previously described by Siegrist et al. (18),
using primers targetingM. smegmatis mbtB,mbtL, irtA, and sigA (18).
ESI-MS studies. Electrospray ionization-mass spectrometry (ESI-
MS) studies were carried out in an ESI-MS spectra recorder with anMSD
SLTrapmass spectrometer (Agilent Technologies) equippedwith an elec-
trospray ionization source. Solutions were analyzed by direct injection.
PZP was dissolved in water-methanol (1:1, vol/vol) to a final concentra-
tion of 10 M, and a ferrous sulfate heptahydrate water solution was
added at a molar ratio 1:1. Data were analyzed with the Thermo Scientific
Xcalibur software.
UV-Vis titration of PZP with Fe2. UV-Vis (UV-visible) spectro-
scopic studies were performed in a PerkinElmer Lambda 10 spectrometer
at room temperature (25°C). Standard 1-cm quartz cuvettes were used to
hold sample and reference solutions. PZP was titrated by sequential addi-
tion of increasing amounts of Fe2 solution to the same cuvette. Briefly, to
a starting 10MPZP solution in DMSO-potassium phosphate buffer (20
mM, pH 7.2), increments of 1 M ferrous sulfate water solution (freshly
made in HCl and hydroxylamine; 1 mM stock solution) were added until
a total concentration of 10 M Fe2 was reached, and then in 2 M
increments until a total concentration of 20 M Fe2 was reached. All
titrations were performed in 20mMpotassium phosphate buffer, pH 7.2.
All solutions were scanned from 240 to 800 nm.
Measurements of the binding constant.UV-Vis spectroscopicmeth-
ods were used for determining apparent binding constants for the forma-
tion of PZP-Fe2 complex in 20mMpotassiumphosphate buffer, pH 7.2.
First, the molar stoichiometry of the complexes formed by titration of 10
MPZPwith increasing amounts of Fe2was determined bymonitoring
the change of absorbance at 400 nm (the wavelength where the complexes
absorb while the ligand does not). The method used was previously de-
scribed for the determination of the apparent binding constant of the
quercetin-Fe2 complex (29). The spectroscopic measurements regis-
tered at 400 nm were used for the calculations.
Competition for Fe2 between PZP and ferrozine. A solution of 3:1
ferrozine-Fe2 (60 M:20 M) mixture in 1 ml of 20 mM potassium
phosphate buffer (pH 7.2) was prepared in a 1-cm-path-length quartz
cuvette. Sixty microliters of PZP (60 M) was added to this solution
after 30 min. The absorbance of the complex was measured every 30
min for 1.5 h.
RESULTS
M. smegmatis is not susceptible to PZP under iron-replete con-
ditions. Based on whole-genome sequencing of threeM. tubercu-
losis mutants conferring resistance to PZP, we previously iden-
tified single mutations, all mapping to rv0283 (eccB3), a gene
encoding a putative transmembrane protein of unknown function
within the esx-3 gene cluster (15). Two of the clones encoded
nonsynonymous EccB3 substitutions, R14L and N24H, while the
third contained a frame-preserving 3-bp deletion that eliminated
N26 from the primary EccB3 sequence (15). These residues are
conserved among mycobacteria (Fig. 1C), and all three localize
to the N-terminal cytosolic tail of EccB3, as predicted by the
TMHMMsoftware (30, 31) (Fig. 1D).M. tuberculosis is dependent
on a functional ESX-3 system for growth (18, 20, 32–34), and all
M. tuberculosis mutations conferring resistance to PZP were
mapped to the esx-3 gene cluster (15). These findings prompted us
to investigate whether PZP could interfere with the activity of
ESX-3 or, alternatively, if ESX-3 could be involved in PZP uptake.
ESX-3 is essential inM. tuberculosis, but not inM. smegmatis (18,
20). Thus, if EccB3 is the cellular target of PZP, M. smegmatis
should not be susceptible to the compound. Indeed, a resazurin
microtiter assay showed that growth was not affected by PZP
when included in the medium up to a 1 mM concentration (re-
sults not shown), and we concluded that M. smegmatis is not af-
fected by PZP under these conditions.
M. smegmatis is susceptible to PZPunder iron-depleted con-
ditions. An M. smegmatis strain disrupted in a gene encoding a
formyl transferase (fxbA) required for exochelin biosynthesis
shows slight growth restriction compared to the WT under iron-
limited conditions (18). When the esx-3 cluster, which is required
formycobactin-mediated iron uptake, is deleted in addition to the
disrupted fxbA gene (esx-3 fxbA::pSES mutant), M. smegmatis
does not grow in low iron, since both themycobactin and exoche-
lin pathways are nonfunctional in this strain. However, an esx-3
knockout with an additional mutation that abolishes mycobactin
synthesis is disrupted in the mycobactin pathway only and thus
grows under low-iron conditions due to production of exochelin
(18). These findings showed that ESX-3 is required for iron acqui-
sition through the mycobactin pathway but not the exochelin
pathway (18). If PZP targetsmycobactin-mediated ironuptake via
ESX-3/EccB3, we reasoned that anM. smegmatismutant unable to
produce exochelin (fxbA) would behave similarly to the esx-3
fxbA::pSES double mutant and not grow in the presence of PZP
under low-iron conditions. To test this hypothesis, we grew the
fxbAmutant in iron-deplete medium (100 M 2,2=-bipyridine)
in the presence of PZP. Surprisingly, PZP inhibited the growth of
all strains under these conditions, including the WT, which we
hypothesizedwould grow due to the production of exochelin (Fig.
2A, left). All strainswere rescued by iron repletion (150MFeCl3)
(Fig. 2A, right). Thus, the action of PZP inM. smegmatis is depen-
dent on low environmental iron.
PZP does not target the ESX-3 secretion system. Our results
showed that production of exochelin could not rescue the cells
from PZP, suggesting a mechanism of action independent of
ESX-3. To further investigate whether the compound impairsmy-
cobacterial growth independently of ESX-3, we analyzed the re-
sponse of an esx-3 whole-locus deletion mutant to PZP. The
Dragset et al.
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growth of the esx-3 mutant was slightly impaired at low iron
levels but not at iron-replete levels compared to the WT strain
(Fig. 2B). However, the growth of bothesx-3 andWT strains was
completely inhibited in the presence of PZP and rescued by the
presence of iron (Fig. 2B). Furthermore, in low iron, theMICs for
bothWT and theesx-3mutant were between 2.5 and 5M (Fig.
2C). Since theesx-3mutant andWT strains showed similar sen-
sitivities to PZP, we concluded that the compound does not target
EccB3 or any other component of the ESX-3 system. In addition,
ESX-3 does not appear responsible for uptake of the compound.
PZP leads to iron accumulation inM. smegmatis.Our obser-
vations suggested that PZP interferes with iron homeostasis. We
hypothesized that the compoundmight interfere with iron uptake
and expected that PZP treatment would result in decreased iron
accumulation. To test this, we analyzed the whole-cell iron con-
tent by atomic absorption spectroscopy. M. smegmatis WT cells
were grown in iron-replete or -deplete medium in the presence or
absence of PZP. We found elevated iron levels in cells grown in
replete medium compared to those grown under iron-deplete
conditions (Fig. 3A, blue bars, minus PZP). Surprisingly, how-
ever, iron accumulation increased in the presence of PZP under
iron-rich conditions (Fig. 3A, blue bars, replete). No difference in
iron content was observed in cells grown in low-iron medium in
the presence or absence of the compound (Fig. 3A, blue bars,
deplete). Since iron accumulated inM. smegmatisWTunder iron-
rich conditions, we compared the iron content in mycobacteria
containing the eccB3 M. tuberculosis resistance mutations. The
R14, N24, and N26 residues are conserved among mycobacteria
(Fig. 1C), suggesting that a mutation in these residues inM. smeg-
matiswould have the same effect as theM. tuberculosismutations.
FIG 2 M. smegmatis is susceptible to PZP in an iron-dependent, ESX-3-independent manner. (A) Growth of M. smegmatis WT and fxbA was monitored by
OD600measurements for 80 h under iron-replete (right) and iron-deplete (left) conditions, in the presence or absence of 25MPZP.M. smegmatisesx-3fxbA
was included as a control. Results are representative of two independent experiments. (B) Growth of M. smegmatis WT and esx-3 was monitored for 70 h in
iron-replete (right) and iron-deplete (left) medium, in the presence or absence of 25 M PZP. (C) Growth of M. smegmatis WT (left) and esx-3 (right) was
monitored for 70 h in iron-deplete medium in the presence of increasing concentrations of PZP. Results shown in panels B and C represent the averages of three
independent biological replicates.
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Hence, we constructed an M. smegmatis eccB3(N26) mutant
strain and analyzed the iron levels. Increased iron accumulation
was observed in the eccB3(N26) mutant in the presence of the
compound under both iron-replete and -deplete conditions (Fig.
3A, white bars).We speculate that themutations in eccB3 increase
the iron acquisition-related activity of ESX-3, leading to increased
iron influx. However, this mutant strain did not show increased
resistance to PZP (Fig. 3C and D). Similarly, increased resistance
to the compound was not observed inM. smegmatis eccB3(R14L)
or eccB3(N24H) strains (results not shown). Given the rather
small shift in the MICs for these mutations that have been re-
ported elsewhere for M. tuberculosis (only a 2.5-fold shift under
iron-rich conditions) (15), it is likely that there is substantial in-
terplay between the environmental iron concentration and resis-
tance, and it remains possible that one could detect resistance of
M. smegmatis eccB3 mutants under optimal iron conditions. At-
tempts to recreate PZP-resistant eccB3mutants inM. tuberculosis
were not successful, perhaps due to the selection of resistant re-
combinants under suboptimal iron conditions (15). Nevertheless,
these results certainly demonstrated that iron accumulates in my-
cobacterial cells in the presence of PZP when sufficient iron is
available in the medium.
PZP-treated M. smegmatis upregulates iron acquisition
genes.Mycobacteria sense iron availability and upregulate acqui-
sition systems in response to iron starvation (35). The increased
iron accumulation seen in the presence of PZP suggested that cells
sense iron starvation and should, therefore, show upregulated
iron acquisition gene expression. Several genes are known to be
iron regulated, including mbtB and mbtL, both of which are in-
volved in mycobactin synthesis but are located in separate gene
clusters (36). Another iron-responsive gene, irtA, encodes a my-
cobactin transporter suggested to couple siderophore import and
iron assimilation together with IrtB (12, 37). Thus, we measured
the expression levels ofmbtB,mbtL, and irtA inM. smegmatis cells
in the presence and absence of PZP. Under iron-deplete condi-
tions, higher expression of iron uptake genes was observed than
under iron-replete conditions (Fig. 3B). All three iron-responsive
genes were, however, further upregulated in the presence of the
compound under both high- and low-iron conditions (Fig. 3B).
Thus, although cells accumulate increased amounts of iron in the
presence of PZP, they simultaneously sense iron starvation.
PZP chelates Fe2.We found that cells treated with PZP accu-
mulate iron but at the same time sense iron starvation. Aiming to
resolve these seemingly contradictory observations, we noted that
PZP has a pyrazolo-[1,5]pyrimidinone core that potentially pos-
sesses Fe2-chelating properties. Thus, we investigated whether
the compound could complex with iron by using ESI-MS with
direct injection of solutions of PZP and Fe2. Figure 4 shows the
ESI-MS spectra of PZP (Fig. 4A) and PZP plus 1 mole equivalent
of Fe2 (Fig. 4B). In addition to the free ligand PZP (m/z 364.17,
FIG 3 Treatment with PZP leads to iron accumulation and upregulation of iron uptake genes in M. smegmatis. (A) Whole-cell iron content was measured by
atomic absorption spectroscopy inM. smegmatisWT and eccB3(N26) strains grown to the late exponential phase in iron-deplete or iron-replete medium for
24 h in the presence () or absence () of 25MPZP. Error bars represent standard errors of at least five biological replicates. (B)M. smegmatisWTwas grown
in iron-deplete or iron-replete medium for 24 h in the presence () or absence () of 25 M PZP. The relative transcript levels of three iron-responsive genes
(mbtB,mbtL, and irtA) were measured by quantitative RT-PCR. Error bars represent the calculated maximum (RQmax) and minimum (RQmin) as determined
from the standard errors of the cycle threshold changes (CT values). (C and D) M. smegmatis WT and eccB3(N26) mutant strains were grown under
iron-depleted conditions with increasing concentrations of PZP, and the OD600 was monitored every second hour.
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[PZP  Na]), two Fe2-PZP complexes were detected at m/z
551.92 and m/z 1078.00 (Fig. 4B) when we mixed PZP and Fe2,
with all displaying the typical iron isotopic pattern (Fig. 4B, in-
sets). In both cases, species corresponding to the formation of the
complex between PZP and Fe2 showed a stoichiometry of 3:1
(m/z 551.92 [Fe2(PZP)2 (PZP – H)Na]
2; m/z 1078.00
[Fe2(PZP)2 (PZP – H)]
). All the other observed peaks did not
fit with the classic iron isotopic pattern.
We further analyzed the ability of PZP to form complexes with
iron by using UV-Vis spectroscopy. The compound was titrated
with increasing amounts of Fe2 (Fig. 5A). The intensities of the
two bands at 275 and 310 nm, which were observed for PZP alone,
decreased after addition of Fe2, whereas the absorbance in the
region above 370 nm increased in intensity. Two isosbestic points
were observed at 300 and 340 nm. These observations fit with the
formation of a PZP-Fe2 complex, since they can be explained by
the delocalization of  electrons of the conjugated PZP ring sys-
tem over the metal core upon PZP-iron binding. The titration
curve confirmed the 3:1 stoichiometry (Fig. 5A, inset) determined
in the ESI-MS spectrometry experiment. Figure 5B shows a pos-
sible chemical structure of the [Fe(PZP)3]
 complex. The condi-
tional binding constant of the compoundwith Fe2was estimated
at 400 nm by applying a method established for measuring the
binding constants of complexes between flavonoids and iron
(29). Since a strong binding constant was determined for the
[Fe(PZP)3]
 complex (K, 	2  1011 mM), we performed com-
petition experiments with ferrozine, a well-known Fe2 chelator
(K, 3.65 1015 mM) (38). Figure 5C shows the changes in absor-
bance of the Fe2-ferrozine complex after addition of PZP. The
peak at 562 nm (Fe2-ferrozine) rose slightly in the first 30 min,
possibly due to the formation of mixed ferrozine-Fe2-PZP com-
plexes; similar complexes have been reported for amino acids and
ferrozine (39). Absorbance increases in the region between 390
and 475 nm indicate the formation of the [Fe(PZP)3]
 complex.
These findings indicate that the formation of this complex occurs
while there is a dissociation of the ferrozine-Fe2 complex. Alto-
gether, these data confirm that PZP can strongly bind Fe2 under
physiological conditions.
FIG 4 PZP chelates Fe2. (A) Electrospray mass spectra of 10 M PZP. (B) Electrospray mass spectra of a solution of 10 M PZP with 10 M Fe2. The inset
shows the isotopic pattern of the peaks at 551.92 and 1078.00 nm. All the reagents were dissolved in water-methanol (1:1, vol/vol).
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DISCUSSION
Nearly all mycobacteria produce the siderophores mycobactins
(4, 5). The saprophytic nonpathogenic mycobacterium M. smeg-
matis produces the siderophore exochelin in addition to the my-
cobactins (6). Mycobactin-mediated iron uptake is dependent on
the type VII mycobacterial secretion system ESX-3, while exoche-
lin-mediated iron uptake is ESX-3 independent (18). The M. tu-
berculosis esx-3 gene cluster is essential for in vitro growth (18, 20,
32–34), andM. tuberculosis is sensitive to PZPunder standard iron
conditions (15). In contrast, M. smegmatis ESX-3 is not essential
for growth and M. smegmatis is protected against PZP in normal
iron medium (18). Interestingly, although the species’ require-
ment for ESX-3 coincides with their susceptibilities to PZP, we
show that ESX-3 is in fact not the cellular target of this compound.
Instead, we found that PZP apparently enters mycobacterial cells
and chelates Fe2 and starves the bacteria for intracellular iron.
In the environment, iron is available as Fe3. Thus, sidero-
phores have been optimized to complex this ion.Once taken up by
the cells though, Fe3 is reduced to Fe2. The affinity of sidero-
phores for Fe3 is extraordinarily high, ranging frombinding con-
stant (K) of 1030 to 1052M (40), far higher than PZP (K	 2 1011
mM). Thus, it is unlikely that this compound could effectively
compete for extracellular iron. Instead, we postulate that the com-
pound enters cells and chelates intracellular Fe2. The affinities of
mycobacterial iron storagemolecules like ferritin and bacteriofer-
ritin for Fe2 are, to our knowledge, unknown.However, the Fe2
affinity of the Escherichia coli bacterioferritin is estimated to be
lower thanK of	1.1 107M, based on competition experiments
with Zn2 (41, 42). It is therefore likely that PZP binds Fe2 in-
tracellularly and deprives the cells of available iron storage and
that the bacteria respond by upregulating the expression of iron
acquisition systems. Given adequate access to extracellular iron,
WT M. smegmatis can overcome the effects of starvation by in-
creasing iron uptake. Similarly, mutations in eccB3 increase intra-
cellular iron levels further. The role of ESX-3 in mycobactin-me-
diated iron uptake is currently unknown.We speculate that ESX-3
FIG 5 PZP competes with ferrozine by binding to iron in a 3:1 stoichiometric manner. (A) Spectroscopic titration of 10 M PZP with Fe2 (increments up to
10 M were reached). (Inset) Absorbance of the PZP-Fe2 complex at 400 nm as a function of Fe2. (B) Chemical structure of (PZP)3-Fe
2 complex. (C)
Competition experiment between ferrozine and PZP for Fe2. Curves: (a, black line), 60 M ferrozine in 20 mM potassium phosphate buffer, pH 7.2 only; (b,
red line) addition of 20 M Fe2; (c, green line) addition of 60 MPZP; (d to f, yellow, purple, and blue lines, respectively) addition of 60 MPZP for 60 min
(d), 90 min (e), or 120 min (f).
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secretes effector molecules important for utilization of mycobac-
tin-bound iron. EccB3 could play a role in regulating secretion of
such effectors, and mutations in the cytosolic tail of EccB3 might
alter effector secretion. Regardless, depriving cells of iron results
in inhibition of cell growth by PZP.
Wells et al. recently identified MmpS4/MmpL4 and MmpS5/
MmpL5 as siderophore export systems inM. tuberculosis (13). An
M. tuberculosis mmpS4 mmpS5 double mutant did not grow
under iron-deplete conditions andwas not fully rescued by adding
hemoglobin as an iron source. However, the growth of M. tuber-
culosismmpS4mmpS5with an additional mutation disrupting
mycobactin synthesis was completely restored by hemoglobin,
suggesting that the lack of mycobactin export leads to accumula-
tion of the siderophore, potentially causing deleterious intracellu-
lar iron chelation (13). PZP could imaginably block exporters of
mycobactins, perhaps by mimicking iron-chelating siderophores,
and mutations in eccB3 could make possible export of mycobac-
tins through ESX-3.We have previously shown a small decrease in
the pool of mycobactins and carboxymycobactins in theM. smeg-
matis esx-3 supernatant filtrate (18). However, this moderate
change in exported mycobactins does not likely account for the
severe esx-3-mediated growth impairment seen with low iron
(18), making a model based on blocking siderophore export via
ESX-3 improbable as a mechanism of PZP.
A streptonigrin sensitivity assay recently suggested that intra-
cellular iron decreases upon repression of esx-3 expression (19).
Conversely, Du Toit Loots et al. used metabolomic approaches to
speculate that an M. smegmatis esx-3 knockout mutant accumu-
lates iron during iron-replete growth (43). It is likely that the re-
sistant eccB3 point mutations influence the iron uptake/assimila-
tion-related properties of ESX-3, leading to increased influx of
iron. However, this alone cannot explain the elevated iron accu-
mulation by the eccB3 mutant on low iron, as we did not see
accumulation in the absence of PZP.
Although the eccB3(N26) mutant accumulates iron also
when grown under low-iron conditions, none of the three M.
smegmatis eccB3 mutants conferred resistance to PZP. However,
we postulate that eccB3 mutations enhance ESX-3-mediated iron
uptake or assimilation, and it is likely that the subtle resistance
effect (2.5-fold) seen in M. tuberculosis was not detectable in M.
smegmatis simply because the cells were grown under iron-defi-
cient conditions and lacked sufficient metal in the medium to
rescue the cells from the compound.
A previous study on structure-activity relationships of com-
pounds structurally related to PZP identified molecules with an
inhibitory effect on M. tuberculosis 1-deoxy-D-xylulose 5-phos-
phate (DXS), an enzyme that combines the mechanisms of pyru-
vate decarboxylase and transketolase (44). Interestingly, DXS ac-
tivity is absolutely dependent on divalent cations (45). It would be
interesting to investigate PZP’s activity on DXS as well as the
chelating properties of these structurally related compounds.
The potential of iron chelators in TB therapeutics has been
investigated previously. Chelators are able to restrict growth of
Mycobacterium avium (46–48), while synthetic mycobactin ana-
logues selectively inhibit M. tuberculosis growth (49). Addition-
ally, iron chelation has proved to inhibit the cytotoxic effect of
mycolactone, a macrolide toxin produced by Mycobacterium ul-
cerans, the causative agent of the necrotizing skin disease Buruli
ulcer (50). A wide spectrum of chelators have furthermore been
designed and synthesized in the search for the treatment of dis-
eases ranging fromacutemyocardial infarction to neurodegenera-
tive diseases and cancer (51–53). Together, these findings demon-
strate a wide range of potential medical applications for iron
chelators that is not restricted to antimycobacterial therapy.
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